Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Malignant Brain Tumours in Children : Present and Future Perspectives

  • Rutka, James T. (Division of Neurosurgery, The Hospital for Sick Children)
  • Received : 2018.02.27
  • Accepted : 2018.04.26
  • Published : 2018.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

In contrast to many of the malignant tumors that occur in the central nervous system in adults, the management, responses to therapy, and future perspectives of children with malignant lesions of the brain hold considerable promise. Within the past 5 years, remarkable progress has been made with our understanding of the basic biology of the molecular genetics of several pediatric malignant brain tumors including medulloblastoma, ependymoma, atypical teratoid rhabdoid tumour, and high grade glioma/diffuse intrinsic pontine glioma. The recent literature in pediatric neuro-oncology was reviewed, and a summary of the major findings are presented. Meaningful sub-classifications of these tumors have arisen, placing children into discrete categories of disease with requirements for targeted therapy. While the mainstay of therapy these past 30 years has been a combination of central nervous system irradiation and conventional chemotherapy, now with the advent of high resolution genetic mapping, targeted therapies have emerged, and less emphasis is being placed on craniospinal irradiation. In this article, the present and future perspective of pediatric brain malignancy are reviewed in detail. The progress that has been made offers significant hope for the future for patients with these tumours.

Keywords

References

  1. Alli S, Figueiredo CA, Golbourn B, Sabha N, Yijun M, Bondoc A, et al. : Brainstem blood brain barrier disruption using focused ultrasound. J Control Release, 2018, under revision
  2. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B : Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59 : 74-79, 1999
  3. Biggs PU, Garen PD, Powers JM, Garvin AJ : Malignant rhabdoid tumor of the central nervous system. Hum Pathol 18 : 332-327, 1987 https://doi.org/10.1016/S0046-8177(87)80161-2
  4. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. : Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31 : 737-754.e6, 2017 https://doi.org/10.1016/j.ccell.2017.05.005
  5. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. : Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7 : 813-820, 2006 https://doi.org/10.1016/S1470-2045(06)70867-1
  6. Gomez S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, Sunol M, de Torres C, et al. : A novel method for rapid molecular subgrouping of medulloblastoma. Clin Cancer Res 24 : 1355-1363, 2018 https://doi.org/10.1158/1078-0432.CCR-17-2243
  7. Guerreiro Stucklin AS, Ramaswamy V, Daniels C, Taylor MD : Review of molecular classication and treatment implications of pediatric brain tumors. Curr Opin Pediatr 30 : 3-9, 2018 https://doi.org/10.1097/MOP.0000000000000562
  8. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, et al. : Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129 : 669-678, 2015 https://doi.org/10.1007/s00401-015-1405-4
  9. Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, Wang X, et al. : Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature 553 : 101-105, 2018
  10. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, et al. : Epig enomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 : 445-450, 2014 https://doi.org/10.1038/nature13108
  11. Morrissy AS, Cavalli FMG, Remke M, Ramaswamy V, Shih DJH, Holgado BL, et al. : Spatial heterogeneity in medulloblastoma. Nat Genet 49 : 780-788, 2017 https://doi.org/10.1038/ng.3838
  12. Muller M, Hubbard SL, Provias J, Greenberg M, Becker LE, Rutka JT : Malignant rhabdoid tumour of the pineal region. Can J Neurol Sci 21 : 273-277, 1994 https://doi.org/10.1017/S0317167100041287
  13. Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. : The whole-genome landscape of medulloblastoma subtypes. Nature 547 : 311-317, 2017 https://doi.org/10.1038/nature22973
  14. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. : Subgroup specific structural variation across 1,000 medulloblastoma genomes. Nature 488 : 49-56, 2012 https://doi.org/10.1038/nature11327
  15. Patterson E, Farr RF : Cerebellar medulloblastoma: treated by irradiation of the whole central nervous system. Acta Radiol 39 : 323-336, 1953 https://doi.org/10.3109/00016925309136718
  16. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, et al. : Pediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14 : 92-107, 2014 https://doi.org/10.1038/nrc3655
  17. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, et al. : Integrated (epi)-Genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell 30 : 891-908, 2016 https://doi.org/10.1016/j.ccell.2016.11.003
  18. Torchia J, Picard D, Lafay-Cousin L, Hawkins CE, Kim SK, Letourneau L, et al. : Molecular subgroups of atypical teratoid rhabdoid tumors in children: an integrated genomic and clinicopathological analysis. Lancet Oncol 16 : 569-582, 2015 https://doi.org/10.1016/S1470-2045(15)70114-2
  19. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al. : Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20 : 143-157, 2011 https://doi.org/10.1016/j.ccr.2011.07.007
  20. Zhou Z, Singh R, Souweidane MM : Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment. Curr Neuropharmacol 15 : 116-128, 2017

Cited by

  1. Current Status and Future Prospects in the Field of Pediatric Tumors vol.28, pp.4, 2018, https://doi.org/10.7887/jcns.28.211
  2. Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy vol.67, pp.12, 2020, https://doi.org/10.1002/pbc.28465